Details

Autor(en) / Beteiligte

• Kernan, Walter N
• Viscoli, Catherine M
• Furie, Karen L
• Young, Lawrence H
• Inzucchi, Silvio E
• Gorman, Mark
• Guarino, Peter D
• Lovejoy, Anne M
• Peduzzi, Peter N
• Conwit, Robin
• Brass, Lawrence M
• Schwartz, Gregory G
• Adams, Harold P
• Berger, Leo
• Carolei, Antonio
• Clark, Wayne
• Coull, Bruce
• Ford, Gary A
• Kleindorfer, Dawn
• O’Leary, John R
• Parsons, Mark W
• Ringleb, Peter
• Sen, Souvik
• Spence, J. David
• Tanne, David
• Wang, David
• Winder, Toni R

Titel

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Ist Teil von

• The New England journal of medicine, 2016-04, Vol.374 (14), p.1321-1331

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In this trial in nondiabetic patients with insulin resistance and a recent ischemic stroke or transient ischemic attack, pioglitazone was associated with a lower risk of stroke and MI than was placebo but with a higher risk of weight gain, edema, and bone fracture. Ischemic stroke and transient ischemic attack (TIA) affect more than 14 million persons worldwide annually. 1 , 2 Affected patients are at increased risk for future cardiovascular events, 3 , 4 and prevention of these adverse outcomes is a major goal in their care. Treatment of insulin resistance represents a potential new preventive strategy that could be added to standard care after ischemic stroke or TIA. 5 Insulin resistance is nearly universal in patients with type 2 diabetes but is also present in more than 50% of patients without diabetes who have had an ischemic stroke or a TIA. 6 The presence of insulin resistance increases . . .